Vaxart Inc. announced plans to release top-line data from its Phase IIb COVID-19 vaccine trial in the first half of 2027. The development is supported by funding from the Biomedical Advanced Research and Development Authority (BARDA).
Vaxart Targets H1 2027 for Phase IIb COVID-19 Data with BARDA Support
|1 min read
BiotechPharmaceuticalsCOVID-19Clinical TrialsHealthcare
